First birth of domestic new drug seen this month

The clinical phase II-b study for Sunpla 50mg inj. (SKI 2053R), a platinum complex anti-cancer drug developed by SK Pharmaceutical Co. was successfully completed and now submitted to the Central Pharmaceutical Evaluation Committee for study review on June 3.

If the Committee accepts its study, the further discussion may be focused on the time for its protocol submission and test report of th...